Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Capital Employed (2016 - 2026)

Ocular Therapeutix has reported Return on Capital Employed over the past 13 years, most recently at 41.44% for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 1036.0% year-over-year to 41.44%; the TTM value through Mar 2026 reached 41.44%, up 1036.0%, while the annual FY2025 figure was 46.38%, 839.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 41.44% at Ocular Therapeutix, up from 48.33% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 22.98% in Q2 2024 and troughed at 90.15% in Q2 2023.
  • A 5-year average of 52.23% and a median of 48.84% in 2022 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: plummeted -4131bps in 2023 and later skyrocketed 6716bps in 2024.
  • Year by year, Return on Capital Employed stood at 64.19% in 2022, then grew by 26bps to 47.81% in 2023, then increased by 17bps to 39.69% in 2024, then decreased by -22bps to 48.33% in 2025, then grew by 14bps to 41.44% in 2026.
  • Business Quant data shows Return on Capital Employed for OCUL at 41.44% in Q1 2026, 48.33% in Q4 2025, and 65.69% in Q3 2025.